Acadian Asset Management LLC grew its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 86.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,705,195 shares of the biopharmaceutical company’s stock after acquiring an additional 791,485 shares during the period. Acadian Asset Management LLC’s holdings in Minerva Neurosciences were worth $5,423,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its stake in shares of Minerva Neurosciences by 226.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,148 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 5,655 shares during the period. Virtu Financial LLC purchased a new stake in shares of Minerva Neurosciences in the 2nd quarter valued at approximately $39,000. Two Sigma Securities LLC purchased a new stake in shares of Minerva Neurosciences in the 2nd quarter valued at approximately $41,000. Sanders Morris Harris LLC purchased a new stake in shares of Minerva Neurosciences in the 3rd quarter valued at approximately $41,000. Finally, Engineers Gate Manager LP purchased a new stake in Minerva Neurosciences during the 2nd quarter worth approximately $57,000. 67.42% of the stock is currently owned by institutional investors and hedge funds.
Shares of Minerva Neurosciences stock opened at $3.68 on Friday. The company has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $4.56. Minerva Neurosciences, Inc. has a 12-month low of $1.81 and a 12-month high of $15.22. The stock has a market cap of $157.04 million, a price-to-earnings ratio of -6.81 and a beta of 1.50.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, November 2nd. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. Analysts expect that Minerva Neurosciences, Inc. will post 0.02 earnings per share for the current year.
A number of equities research analysts have commented on NERV shares. William Blair reissued a “hold” rating on shares of Minerva Neurosciences in a research report on Friday, September 11th. Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $6.20.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia.
Further Reading: How is net asset value different from market price?
Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences, Inc. (NASDAQ:NERV).
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.